GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

Search

Elekta AB

Abierto

56.25 0.45

Resumen

Variación precio

24h

Actual

Mínimo

55.65

Máximo

56.55

Métricas clave

By Trading Economics

Ingresos

94M

230M

Ventas

424M

4.1B

P/B

Media del Sector

74.079

76.798

BPA

0.64

Rentabilidad por dividendo

4.32

Margen de beneficio

5.651

Empleados

4,484

EBITDA

20M

529M

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

4.32%

2.37%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

4.9B

22B

Apertura anterior

55.8

Cierre anterior

56.25

Elekta AB Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

18 dic 2025, 23:54 UTC

Acciones populares

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dic 2025, 23:51 UTC

Ganancias

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dic 2025, 23:39 UTC

Principales Movimientos del Mercado

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dic 2025, 22:57 UTC

Adquisiciones, fusiones, absorciones

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dic 2025, 21:40 UTC

Ganancias

Nike Sales Tick Up, But China Weakness Persists

18 dic 2025, 23:45 UTC

Charlas de Mercado

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dic 2025, 23:37 UTC

Charlas de Mercado
Ganancias

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dic 2025, 23:36 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dic 2025, 23:03 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dic 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dic 2025, 23:00 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dic 2025, 22:59 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dic 2025, 22:58 UTC

Adquisiciones, fusiones, absorciones

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dic 2025, 22:57 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dic 2025, 22:56 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dic 2025, 22:55 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:59 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

18 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 dic 2025, 21:35 UTC

Ganancias

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dic 2025, 21:31 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Greater China Rev Down 17% >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q EPS 53c >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Apparel Rev $3.91B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Equipment Rev $550M >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q N Amer Rev $5.63B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Footwear Rev $7.66B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Greater China Rev $1.42B >NKE

Comparación entre iguales

Cambio de precio

Elekta AB Esperado

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Elekta AB

Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software. In addition, the company offers Elekta ONE, a software suite of multiple Elekta solutions. Further, it provides brachytherapy products, including Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Elekta Xoft Axxent, and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Additionally, the company offers neurosurgery products, such as Leksell Vantage Stereotactic System for intracranial neurosurgery. Furthermore, it provides Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
help-icon Live chat